MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584394 | Name: Syrosingopine
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Syrosingopine is a metformin synergist which can potentiate the anticancer activity of widely used diabetic drug metformin by sensitizing cancer cells to metformin.

Chemical Structure

Syrosingopine
Syrosingopine
CAS#84-36-6

Theoretical Analysis

MedKoo Cat#: 584394

Name: Syrosingopine

CAS#: 84-36-6

Chemical Formula: C35H42N2O11

Exact Mass: 666.2789

Molecular Weight: 666.72

Elemental Analysis: C, 63.05; H, 6.35; N, 4.20; O, 26.40

Price and Availability

Size Price Availability Quantity
5mg USD 350.00
25mg USD 750.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Syrosingopine; HF-41T; SU 3118
IUPAC/Chemical Name
3beta,20alpha-Yohimban-16beta-carboxylic acid, 18beta-hydroxy-11,17alpha-dimethoxy-, methyl ester, 4-hydroxy-3,5-dimethoxybenzoate (ester) ethyl carbonate (ester) (8CI)
InChi Key
ZCDNRPPFBQDQHR-SSYATKPKSA-N
InChi Code
InChI=1S/C35H42N2O11/c1-7-46-35(40)48-31-26(42-3)12-18(13-27(31)43-4)33(38)47-28-14-19-17-37-11-10-22-21-9-8-20(41-2)15-24(21)36-30(22)25(37)16-23(19)29(32(28)44-5)34(39)45-6/h8-9,12-13,15,19,23,25,28-29,32,36H,7,10-11,14,16-17H2,1-6H3/t19-,23+,25-,28-,29+,32+/m1/s1
SMILES Code
[H][C@@]12C(NC3=C4C=CC(OC)=C3)=C4CCN1C[C@]5(C[C@@H](OC(C6=CC(OC)=C(OC(OCC)=O)C(OC)=C6)=O)[C@H](OC)[C@@H](C(OC)=O)[C@]5(C2)[H])[H]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Certificate of Analysis
View CoA: current batch, Lot#A9O03B21
Safety Data Sheet (SDS)
View Safety Data Sheet (SDS)
Instruction
View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 666.72 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: SHELBURNE PF, ORGAIN ES. Comparison of syrosingopine and reserpine in the treatment of ambulatory hypertensive patients. Am J Med Sci. 1963 Mar;245:304-10. PubMed PMID: 13977067. 2: Walsh TJ, Palfai T. Peripheral catecholamines and memory: characteristics of syrosingopine-induced amnesia. Pharmacol Biochem Behav. 1979 Oct;11(4):449-52. PubMed PMID: 42929. 3: NEW AND Nonofficial Drugs: syrosingopine. J Am Med Assoc. 1959 Aug 22;170(17):2092. PubMed PMID: 13672811. 4: Furukawa T, Sano T, Kohno Y, Koga M, Nagasaki N. Selective depleting effect of syrosingopine on brain catecholamine levels with relation to morphine analgesia in the rat. Pharmacol Biochem Behav. 1976 Apr;4(4):419-25. PubMed PMID: 6976. 5: Palfai T, Wichlinski L, Brown HA, Brown OM. Effects of amnesic doses of reserpine or syrosingopine on mouse brain acetylcholine levels. Pharmacol Biochem Behav. 1986 May;24(5):1457-9. PubMed PMID: 2873591. 6: RAAB W, MARCHET H, HERRLICH HC. Effect of reserpine and syrosingopine on the rate and contractility of the human heart. Am J Cardiol. 1961 Mar;7:404-11. PubMed PMID: 13738780. 7: Palfai T, Wichlinski L, Brown OM. The effect of reserpine, syrosingopine, and guanethidine on the retention of discriminated escape reversal: peripherally administered catecholamines cannot reverse the reserpine amnesia in this situation. Behav Neural Biol. 1983 May;38(1):120-6. PubMed PMID: 6138025. 8: Benjamin D, Colombi M, Hindupur SK, Betz C, Lane HA, El-Shemerly MY, Lu M, Quagliata L, Terracciano L, Moes S, Sharpe T, Wodnar-Filipowicz A, Moroni C, Hall MN. Syrosingopine sensitizes cancer cells to killing by metformin. Sci Adv. 2016 Dec 23;2(12):e1601756. doi: 10.1126/sciadv.1601756. eCollection 2016 Dec. PubMed PMID: 28028542; PubMed Central PMCID: PMC5182053. 9: BARE WW. Hypertension and edema in the aged. Comparison of hydrochlorothiazide and a hydrochlorothiazide-syrosingopine combination. J Am Geriatr Soc. 1960 Oct;8:795-802. PubMed PMID: 24545433. 10: Camanni E, Strumia E, Portaleone P, Molinatti GM. Prolactin secretion during reserpine and syrosingopine treatment. Eur J Clin Pharmacol. 1981;20(5):347-9. PubMed PMID: 6116608. 11: Walsh TJ, Palfai T. Memory storage impairment or retrieval failure: pharmacologically distinguishable processes. Pharmacol Biochem Behav. 1979 Oct;11(4):453-6. PubMed PMID: 574972. 12: HERRMANN GR, VOGELPOHL EB, HEJTMANCIK MR, WRIGHT JC. Therapy of hypertension with orally given syrosingopine. J Am Med Assoc. 1959 Apr 4;169(14):1609-12. PubMed PMID: 13640910. 13: KERT MJ, MAILMAN RH, ROTH SI, WITHERBEE H, AVEDON M. Clinical evaluation of a new reserpine derivative, SU-3118 (syrosingopine). Angiology. 1960 Feb;11:31-4. PubMed PMID: 14408654. 14: QUINTON RM. THE INCREASE IN THE TOXICITY OF YOHIMBINE INDUCED BY IMIPRAMINE AND OTHER DRUGS IN MICE. Br J Pharmacol Chemother. 1963 Aug;21:51-66. PubMed PMID: 14066151; PubMed Central PMCID: PMC1703860. 15: SCHMITT H. [Hypertensive action of syrosingopine after ephedrine]. C R Seances Soc Biol Fil. 1960;154:55-7. French. PubMed PMID: 14443141. 16: Shibuya T, Sato K. Fluorescence histochemical studies of the effects of rauwolfia alkaloid derivatives on adrenergic vasomotor nerves. Int J Clin Pharmacol Ther Toxicol. 1985 Jan;23(1):5-10. PubMed PMID: 2859253. 17: LEROY JG, DE SCHAEPDRYVER AF. Catecholamine levels of brain and heart in mice after iproniazid, syrosingopine and 10-methoxydeserpidine. Arch Int Pharmacodyn Ther. 1961 Feb 1;130:231-4. PubMed PMID: 13761108. 18: Palfai T, Walsh TJ. Comparison of the long-term cumulative effects of reserpine and syrosingopine on general activity. Pharmacol Biochem Behav. 1979 Nov;11(5):585-7. PubMed PMID: 43517. 19: Pham-Huu-Chanh, De Schaepdryver AF. On the pharmacology of syrosingopine and reserpine. Arch Int Pharmacodyn Ther. 1965 Sep;157(1):207-13. PubMed PMID: 4380062. 20: CALESNICK B. Reduced sedative effect of a newly synthesized reserpine derivative (syrosingopine): clinical appraisal in primary hypertension. J Am Geriatr Soc. 1959 Aug;7(8):648-55. PubMed PMID: 13672741.

View History

Kaitocephalin

Kaitocephalin